Free Trial

This company has been marked as potentially delisted and may not be actively trading.

OTCMKTS:ICOTF

iCo Therapeutics (ICOTF) Stock Price, News & Analysis

iCo Therapeutics logo

About iCo Therapeutics Stock (OTCMKTS:ICOTF)

Advanced Chart

Key Stats

Today's Range
$0.50
$0.59
50-Day Range
$0.30
$0.42
52-Week Range
$0.80
$1.82
Volume
209,262 shs
Average Volume
4,760 shs
Market Capitalization
$5.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

Receive ICOTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iCo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ICOTF Stock News Headlines

MSCLF Satellos Bioscience Inc.
ICO Group Ltd.
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Satellos Bioscience Inc (MSCL)
See More Headlines

Company Calendar

Today
5/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ICOTF
CIK
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-1,110,000.00
Pretax Margin
-4,148.78%

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.07) per share
Price / Book
-7.98

Miscellaneous

Free Float
N/A
Market Cap
$5.06 million
Optionable
Not Optionable
Beta
2.03
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (OTCMKTS:ICOTF) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners